tiprankstipranks
Trending News
More News >
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
US Market
Advertisement

TransMedics Group (TMDX) Stock Forecast & Price Target

Compare
1,658 Followers
See the Price Targets and Ratings of:

TMDX Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
8 Buy
3 Hold
0 Sell
Based on 11 analysts giving stock ratings to
TransMedics
Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TMDX Stock 12 Month Forecast

Average Price Target

$144.11
▲(19.96% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $144.11 with a high forecast of $170.00 and a low forecast of $115.00. The average price target represents a 19.96% change from the last price of $120.13.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"61":"$61","116":"$116","171":"$171","88.5":"$88.5","143.5":"$143.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$170.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":144.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$144.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$115.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[61,88.5,116,143.5,171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.89,119.12923076923077,123.36846153846153,127.6076923076923,131.84692307692308,136.08615384615385,140.32538461538462,144.5646153846154,148.80384615384617,153.0430769230769,157.28230769230768,161.52153846153846,165.76076923076923,{"y":170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.89,117.1376923076923,119.38538461538462,121.63307692307693,123.88076923076923,126.12846153846155,128.37615384615384,130.62384615384616,132.87153846153848,135.11923076923077,137.3669230769231,139.6146153846154,141.8623076923077,{"y":144.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.89,114.89846153846153,114.90692307692308,114.91538461538461,114.92384615384616,114.93230769230769,114.94076923076923,114.94923076923077,114.95769230769231,114.96615384615384,114.97461538461539,114.98307692307692,114.99153846153847,{"y":115,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":144.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.89,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$170.00Average Price Target$144.11Lowest Price Target$115.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$170
Buy
41.51%
Upside
Reiterated
10/21/25
Buy Rating for TransMedics Group: Transformative Organ Care System Enhances Transplant Efficiency and Expands Usable Organ SupplyWe are tracking monthly U.S. heart, liver, and lung transplant volumes and TransMedics Aviation flights. TMDX has moved beyond the early innings of the Organ Care System (OCS) and National OCS Program (NOP) launches, so quarterly revenue performances have become levered to US transplant market trends and TransMedics Aviation flight runs, which face known annual seasonality headwinds in 3Q.
TR | OpenAI - 4o Analyst forecast on TMDX
TR | OpenAI - 4o
TR | OpenAI - 4o
$125$130
Buy
8.22%
Upside
Reiterated
10/17/25
AI Generated ArticleAI Generated Article
Stifel Nicolaus Analyst forecast on TMDX
Stifel Nicolaus
Stifel Nicolaus
$115
Hold
-4.27%
Downside
Reiterated
10/14/25
Stifel Nicolaus Reaffirms Their Hold Rating on TransMedics Group (TMDX)
Canaccord Genuity Analyst forecast on TMDX
Canaccord Genuity
Canaccord Genuity
$142
Buy
18.21%
Upside
Reiterated
10/13/25
TransMedics Group (TMDX) Gets a Buy from Canaccord Genuity
Jefferies Analyst forecast on TMDX
Jefferies
Jefferies
$145
Buy
20.70%
Upside
Initiated
10/13/25
Buy Rating for TransMedics Group: Innovative Organ Care System and Promising Growth Prospects
Evercore ISI
$155
Buy
29.03%
Upside
Reiterated
10/07/25
TransMedics added to 'Tactical Underperform' list at Evercore ISITransMedics added to 'Tactical Underperform' list at Evercore ISI
Oppenheimer Analyst forecast on TMDX
Oppenheimer
Oppenheimer
$150
Buy
24.86%
Upside
Reiterated
10/03/25
Oppenheimer Reaffirms Their Buy Rating on TransMedics Group (TMDX)
William Blair Analyst forecast on TMDX
William Blair
William Blair
Buy
Reiterated
10/03/25
TransMedics Group: Strong Long-Term Investment Despite Short-Term Sales FluctuationsWe believe TransMedics may fall modestly short of consensus sales estimates this quarter, mainly due to typical seasonal weakness in industry transplant volumes. More specific, based on our analysis of flight volume trends in the period (detailed below), we believe third-quarter revenue could approximate $140 million, which is roughly 4% below the current Street estimate of $145.3 million. Our projections are further supported by monthly organ transplant activity through the third quarter (also detailed below), which also indicates seasonal industry weakness.
Needham
Hold
Reiterated
09/23/25
Hold Rating for TransMedics Group Amid Uncertain Transplant Volume and Sales Projections
Morgan Stanley Analyst forecast on TMDX
Morgan Stanley
Morgan Stanley
$123
Hold
2.39%
Upside
Reiterated
09/18/25
Hold Rating on TransMedics Amid Regulatory Changes in Organ Transplant Sector
Piper Sandler Analyst forecast on TMDX
Piper Sandler
Piper Sandler
$145
Buy
20.70%
Upside
Reiterated
09/03/25
Piper Sandler Sticks to Its Buy Rating for TransMedics Group (TMDX)
Robert W. Baird Analyst forecast on TMDX
Robert W. Baird
Robert W. Baird
$148$152
Buy
26.53%
Upside
Reiterated
07/31/25
TransMedics price target raised to $152 from $148 at BairdTransMedics price target raised to $152 from $148 at Baird
J.P. Morgan Analyst forecast on TMDX
J.P. Morgan
J.P. Morgan
$81$114
Hold
-5.10%
Downside
Reiterated
05/09/25
TransMedics Group (TMDX) PT Raised to $114 at JPMorganJPMorgan analyst Allen Gong raised the price target on TransMedics Group (NASDAQ: TMDX) to $114.00 (from $81.00) while maintaining a Neutral rating.
Nephron Analyst forecast on TMDX
Unknown Analyst
Nephron
Not Ranked
Nephron
$105
Buy
-12.59%
Downside
Initiated
01/06/25
Nephron starts TransMedics Group (TMDX) at BuyNephron initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Buy rating and a price target of $105.00.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$170
Buy
41.51%
Upside
Reiterated
10/21/25
Buy Rating for TransMedics Group: Transformative Organ Care System Enhances Transplant Efficiency and Expands Usable Organ SupplyWe are tracking monthly U.S. heart, liver, and lung transplant volumes and TransMedics Aviation flights. TMDX has moved beyond the early innings of the Organ Care System (OCS) and National OCS Program (NOP) launches, so quarterly revenue performances have become levered to US transplant market trends and TransMedics Aviation flight runs, which face known annual seasonality headwinds in 3Q.
TR | OpenAI - 4o Analyst forecast on TMDX
TR | OpenAI - 4o
TR | OpenAI - 4o
$125$130
Buy
8.22%
Upside
Reiterated
10/17/25
AI Generated ArticleAI Generated Article
Stifel Nicolaus Analyst forecast on TMDX
Stifel Nicolaus
Stifel Nicolaus
$115
Hold
-4.27%
Downside
Reiterated
10/14/25
Stifel Nicolaus Reaffirms Their Hold Rating on TransMedics Group (TMDX)
Canaccord Genuity Analyst forecast on TMDX
Canaccord Genuity
Canaccord Genuity
$142
Buy
18.21%
Upside
Reiterated
10/13/25
TransMedics Group (TMDX) Gets a Buy from Canaccord Genuity
Jefferies Analyst forecast on TMDX
Jefferies
Jefferies
$145
Buy
20.70%
Upside
Initiated
10/13/25
Buy Rating for TransMedics Group: Innovative Organ Care System and Promising Growth Prospects
Evercore ISI
$155
Buy
29.03%
Upside
Reiterated
10/07/25
TransMedics added to 'Tactical Underperform' list at Evercore ISITransMedics added to 'Tactical Underperform' list at Evercore ISI
Oppenheimer Analyst forecast on TMDX
Oppenheimer
Oppenheimer
$150
Buy
24.86%
Upside
Reiterated
10/03/25
Oppenheimer Reaffirms Their Buy Rating on TransMedics Group (TMDX)
William Blair Analyst forecast on TMDX
William Blair
William Blair
Buy
Reiterated
10/03/25
TransMedics Group: Strong Long-Term Investment Despite Short-Term Sales FluctuationsWe believe TransMedics may fall modestly short of consensus sales estimates this quarter, mainly due to typical seasonal weakness in industry transplant volumes. More specific, based on our analysis of flight volume trends in the period (detailed below), we believe third-quarter revenue could approximate $140 million, which is roughly 4% below the current Street estimate of $145.3 million. Our projections are further supported by monthly organ transplant activity through the third quarter (also detailed below), which also indicates seasonal industry weakness.
Needham
Hold
Reiterated
09/23/25
Hold Rating for TransMedics Group Amid Uncertain Transplant Volume and Sales Projections
Morgan Stanley Analyst forecast on TMDX
Morgan Stanley
Morgan Stanley
$123
Hold
2.39%
Upside
Reiterated
09/18/25
Hold Rating on TransMedics Amid Regulatory Changes in Organ Transplant Sector
Piper Sandler Analyst forecast on TMDX
Piper Sandler
Piper Sandler
$145
Buy
20.70%
Upside
Reiterated
09/03/25
Piper Sandler Sticks to Its Buy Rating for TransMedics Group (TMDX)
Robert W. Baird Analyst forecast on TMDX
Robert W. Baird
Robert W. Baird
$148$152
Buy
26.53%
Upside
Reiterated
07/31/25
TransMedics price target raised to $152 from $148 at BairdTransMedics price target raised to $152 from $148 at Baird
J.P. Morgan Analyst forecast on TMDX
J.P. Morgan
J.P. Morgan
$81$114
Hold
-5.10%
Downside
Reiterated
05/09/25
TransMedics Group (TMDX) PT Raised to $114 at JPMorganJPMorgan analyst Allen Gong raised the price target on TransMedics Group (NASDAQ: TMDX) to $114.00 (from $81.00) while maintaining a Neutral rating.
Nephron Analyst forecast on TMDX
Unknown Analyst
Nephron
Not Ranked
Nephron
$105
Buy
-12.59%
Downside
Initiated
01/06/25
Nephron starts TransMedics Group (TMDX) at BuyNephron initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Buy rating and a price target of $105.00.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TransMedics Group

1 Month
xxx
Success Rate
19/31 ratings generated profit
61%
Average Return
+5.89%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.29% of your transactions generating a profit, with an average return of +5.89% per trade.
3 Months
xxx
Success Rate
19/31 ratings generated profit
61%
Average Return
+15.33%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.29% of your transactions generating a profit, with an average return of +15.33% per trade.
1 Year
William PlovanicCanaccord Genuity
Success Rate
23/31 ratings generated profit
74%
Average Return
+47.94%
reiterated a buy rating 10 days ago
Copying William Plovanic's trades and holding each position for 1 Year would result in 74.19% of your transactions generating a profit, with an average return of +47.94% per trade.
2 Years
xxx
Success Rate
26/31 ratings generated profit
84%
Average Return
+94.19%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 83.87% of your transactions generating a profit, with an average return of +94.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TMDX Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
0
2
2
3
1
Buy
19
23
26
27
28
Hold
8
12
11
12
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
37
39
42
37
In the current month, TMDX has received 29 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. TMDX average Analyst price target in the past 3 months is 144.11.
Each month's total comprises the sum of three months' worth of ratings.

TMDX Financial Forecast

TMDX Earnings Forecast

Next quarter’s earnings estimate for TMDX is $0.36 with a range of $0.24 to $0.51. The previous quarter’s EPS was $0.92. TMDX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year TMDX has Preformed in-line its overall industry.
Next quarter’s earnings estimate for TMDX is $0.36 with a range of $0.24 to $0.51. The previous quarter’s EPS was $0.92. TMDX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year TMDX has Preformed in-line its overall industry.

TMDX Sales Forecast

Next quarter’s sales forecast for TMDX is $144.62M with a range of $139.40M to $149.00M. The previous quarter’s sales results were $157.37M. TMDX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year TMDX has Preformed in-line its overall industry.
Next quarter’s sales forecast for TMDX is $144.62M with a range of $139.40M to $149.00M. The previous quarter’s sales results were $157.37M. TMDX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year TMDX has Preformed in-line its overall industry.

TMDX Stock Forecast FAQ

What is TMDX’s average 12-month price target, according to analysts?
Based on analyst ratings, TransMedics Group Inc’s 12-month average price target is 144.11.
    What is TMDX’s upside potential, based on the analysts’ average price target?
    TransMedics Group Inc has 19.96% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TMDX a Buy, Sell or Hold?
          TransMedics Group Inc has a consensus rating of Moderate Buy which is based on 8 buy ratings, 3 hold ratings and 0 sell ratings.
            What is TransMedics Group Inc’s price target?
            The average price target for TransMedics Group Inc is 144.11. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $170.00 ,the lowest forecast is $115.00. The average price target represents 19.96% Increase from the current price of $120.13.
              What do analysts say about TransMedics Group Inc?
              TransMedics Group Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of TMDX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis